OpenComing Soon (1–3 yrs) Treatment Study
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
For Condition: Obesity or OverweightFor Condition: Type 2 Diabetes Mellitus
ID: NCT07351058
Horizon Patient Guidance Summary
Our intelligence engine has synthesized this trial record to answer your most important questions in clear, simple terms:
How it’s taken
Pills / Oral Tablets
Expected Availability Horizon
Coming Soon (1–3 yrs away)
StageAdvanced Clinical Stage : Large-scale testing in thousands of patients. The final benchmark comparison phase closest to FDA approval and commercial release.
EligibleThis study is looking exclusively for patients diagnosed with the condition.
About This Clinical Trial
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants with obesity or overweight and Type 2 diabetes mellitus (T2DM).
Study Timeline & Quick Facts
Trial Status
Open — Looking for Participants
Total Target Enrollment
1.6K patients (Estimated)
Study Start Date
2026-03-23
Est. Primary Completion
2028-08-07
Tested Drugs & Treatment Groups
COMBINATION_PRODUCTPlacebo
Placebo will be volume-matched and administered once weekly using an integrated drug-device combination product.
COMBINATION_PRODUCTEnicepatide
Enicepatide will be administered once weekly at the randomized dosing regimen using an integrated drug-device combination product.
Treatment Arms Description
PLACEBO_COMPARATORArm 1: Placebo
EXPERIMENTALArm 2: Enicepatide Dosing Regimen 1
EXPERIMENTALArm 3: Enicepatide Dosing Regimen 2
EXPERIMENTALArm 4: Enicepatide Dosing Regimen 3
Can I Join This Study?
Suitable For
Everyone welcome
Ages Welcome
18 Years and older
Full Criteria Checklist
Who Can Join
- Ability and willingness to self-administer the study drug (or receive an injection from a trained individual if visually impaired or with physical limitations)
- Diagnosis of type 2 diabetes mellitus (T2DM) according to WHO classification or other locally applicable standards with HbA1c ≥6.5% to ≤10% determined by laboratory test at screening, and on stable oral therapy for at least 3 months prior to screening (if applicable). T2DM may be treated with diet/exercise alone or any oral anti-hyperglycemic medication (as per local labeling) EXCEPT dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1 RA-based therapy.
- Body mass index (BMI) ≥27.0 kg/m\^2
- History of ≥1 self-reported unsuccessful diet/exercise effort to lose body weight
Who Cannot Join
- History of type 1 diabetes mellitus (T1DM) or any lifetime history of ketoacidosis or history of hyperosmolar state/coma within 12 months prior to screening
- Have had 1 or more episodes of severe hypoglycemia and/or has hypoglycemia unawareness within the 6 months prior to screening
- At least 2 confirmed fasting blood glucose values \>270 mg/dL (15.0 mmol/L) (on 2 non-consecutive days) during screening
- Self-reported change in body weight \>5 kg within 3 months prior to screening
- Obesity induced by other endocrinologic disorders (e.g., Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., melanocortin 4 receptor deficiency or Prader-Willi syndrome)
- Prior or planned surgical treatment for obesity. Liposuction or abdominoplasty if performed more than 1 year prior to screening is allowed.
- Known clinically significant gastric emptying abnormality (e.g., severe gastroparesis or gastric outlet obstruction)
- Poorly controlled hypertension at screening
- Have any of the following cardiovascular conditions within 3 months prior to screening: Acute myocardial infarction; Cerebrovascular accident (stroke)/transient ischemic attack; Unstable angina; Hospitalization due to congestive heart failure
- Treatment with any approved or investigational GLP-1-RA-based therapy (e.g., GLP-1 receptor mono agonist, GLP-1/GIP receptor dual agonist, GLP-1/GIP/Gluc receptor triple agonist) within 6 months prior to randomization
What is this Study Measuring?
Primary Outcome Measures
- Percent (%) Change from Baseline in Body Weight at Week 72 — Time Frame: Baseline through Week 72
View Secondary Outcome Measures (40)
- Percentage of Participants Achieving ≥5% Body Weight Loss from Baseline at Week 72 — Time Frame: Baseline and Week 72
- Percentage of Participants Achieving ≥10% Body Weight Loss from Baseline at Week 72 — Time Frame: Baseline and Week 72
- Percentage of Participants Achieving ≥15% Body Weight Loss from Baseline at Week 72 — Time Frame: Baseline and Week 72
- Change from Baseline in Body Weight (kg) at Week 72 — Time Frame: Baseline through Week 72
- Change from Baseline in Hemoglobin A1c (HbA1c) at Week 72 — Time Frame: Baseline through Week 72
- Percentage of Participants Achieving HbA1c of ≤6.5% at Week 72 — Time Frame: Week 72
- Percentage of Participants Achieving HbA1c of <7% at Week 72 — Time Frame: Week 72
- Change from Baseline in Waist Circumference (cm) at Week 72 — Time Frame: Baseline through Week 72
- Change from Baseline in Fasting Glucose at Week 72 — Time Frame: Baseline through Week 72
- Change from Baseline in Fasting Insulin at Week 72 — Time Frame: Baseline through Week 72
Where to Participate
This trial is recruiting at 210 study facilities worldwide. Click below to see if there is a clinic or hospital in your area:
Show All 210 Facilities & Contact Sites
Lakeview Clinical Research
Guntersville, Alabama, United States
Status: Open
Arizona Clinical Trials
Tucson, Arizona, United States
Status: Open
University of California Irvine
Irvine, California, United States
Status: Open
Orange County Research Center
Lake Forest, California, United States
Status: Open
Ark Clinical Research
Long Beach, California, United States
Status: Open
Catalina Research Institute, LLC
Montclair, California, United States
Status: Open
Infinity Clinical Research
Norco, California, United States
Status: Open
Prospective Research Innovations Inc.
Rancho Cucamonga, California, United States
Status: Open
Encompass Clinical Research
Spring Valley, California, United States
Status: Open
Emerson Clinical Research Institute
Washington D.C., District of Columbia, United States
Status: Open
Tampa Bay Medical Research, Inc.
Clearwater, Florida, United States
Status: Open
Center for Diabetes, Obesity and Metabolism Inc
Pembroke Pines, Florida, United States
Status: Open
Progressive Medical Research
Port Orange, Florida, United States
Status: Open
Eirvera, LLC
St. Petersburg, Florida, United States
Status: Open
Centricity Research Columbus Georgia Multispecialty
Columbus, Georgia, United States
Status: Open
Atlanta Veterans Affairs Medical Center
Decatur, Georgia, United States
Status: Open
Rophe Adult and Pediatric Medicine/SKYCRNG
Union City, Georgia, United States
Status: Open
Elite Clinical Trials
Blackfoot, Idaho, United States
Status: Open
Central Illinois Diabetes and Clinical Research
Springfield, Illinois, United States
Status: Open
Elevate Clinical Research
Lake Charles, Louisiana, United States
Status: Open
Nola Care Clinical Research Center
Metairie, Louisiana, United States
Status: Open
DelRicht Clinical Research, LLC
New Orleans, Louisiana, United States
Status: Open
Centennial Medical Group
Columbia, Maryland, United States
Status: Open
Olive Branch Family Medical Center
Olive Branch, Mississippi, United States
Status: Open
Kansas City VA Medical Center
Kansas City, Missouri, United States
Status: Open
Centricity Research Morehead City Multispeciality
Morehead City, North Carolina, United States
Status: Open
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
Status: Open
Remington Davis Inc
Columbus, Ohio, United States
Status: Open
Lynn Institute of Norman
Norman, Oklahoma, United States
Status: Open
Lynn Health Science Institute
Oklahoma City, Oklahoma, United States
Status: Open
Essential Medical Research
Tulsa, Oklahoma, United States
Status: Open
VA Pittsburgh Healthcare System
Pittsburgh, Pennsylvania, United States
Status: Open
Coastal Carolina Research Center
North Charleston, South Carolina, United States
Status: Open
Circle Clinical Research
Sioux Falls, South Dakota, United States
Status: Open
Headlands Research Brownsville
Brownsville, Texas, United States
Status: Open
Velocity Clinical Research
Dallas, Texas, United States
Status: Open
South Texas Research Institute - Edinburg
Edinburg, Texas, United States
Status: Open
HRI ? Medical Center, LLC
Houston, Texas, United States
Status: Open
Juno Research, LLC
Houston, Texas, United States
Status: Open
HRI ? Pasadena, LLC
Pasadena, Texas, United States
Status: Open
Pinnacle Clinical Research - San Antonio
San Antonio, Texas, United States
Status: Open
DM Clinical Research
Tomball, Texas, United States
Status: Open
Manassas Clinical Research Center
Manassas, Virginia, United States
Status: Open
Centricity Research Suffolk Primary Care
Suffolk, Virginia, United States
Status: Open
Era Health Research
Redmond, Washington, United States
Status: Open
CINME
Buenos Aires, Argentina
Status: Open
CEDIC Centro de Investigaciones Clinicas
Buenos Aires, Argentina
Status: Open
Centro Medico Viamonte SRL
Buenos Aires, Argentina
Status: Open
IME - Instituto Médico Especializado
Buenos Aires, Argentina
Status: Open
Instituto centenario
Ciudad Autonoma Buenos Aires, Argentina
Status: Open
Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
Ciudad Autonoma Buenos Aires, Argentina
Status: Open
Centro de Investigaciones Medicas Mar Del Plata
Mar del Plata, Argentina
Status: Open
Paratus Clinical Western Sydney
Blacktown, New South Wales, Australia
Status: Open
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Status: Open
Logan Hospital
Meadowbrook, Queensland, Australia
Status: Open
Southern Adelaide Diabetes and Endocrine Services (SADES)
Oaklands Park, South Australia, Australia
Status: Open
Heidelberg Repatriation Hospital
Heidelberg, Victoria, Australia
Status: Open
Baker Heart and Diabetes Insitute
Melbourne, Victoria, Australia
Status: Open
HC-UFG - Hospital das Clínicas da Universidade Federal de Goiás
Goiânia, Goiás, Brazil
Status: Open
Nucleo de Pesquisa Clinica do Rio Grande do Sul NPCR
Porto Alegre, Rio Grande do Sul, Brazil
Status: Open
Clinica do Coracao
Aracaju, Sergipe, Brazil
Status: Open
Hospital de Base de Sao Jose do Rio Preto
São José do Rio Preto, São Paulo, Brazil
Status: Open
CPQuali Pesquisa Clinica Ltda
São Paulo, São Paulo, Brazil
Status: Open
Centro de Pesquisas Clinicas
São Paulo, São Paulo, Brazil
Status: Open
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo
São Paulo, São Paulo, Brazil
Status: Open
IBPCLIN Instituto Brasil de Pesquisa Clinica
Rio de Janeiro, Brazil
Status: Open
Centricity Research Calgary Endocrinology
Calgary, Alberta, Canada
Status: Open
TGElliott Inc. dba BC Diabetes
Vancouver, British Columbia, Canada
Status: Open
Centricity Research Brampton Endocrinology
Brampton, Ontario, Canada
Status: Open
Medicor Research Inc
Greater Sudbury, Ontario, Canada
Status: Open
LMC Clinical Research Inc
Toronto, Ontario, Canada
Status: Open
Applied Medical Informatics Research Inc. (A.M.I.R.)
Montreal, Quebec, Canada
Status: Open
Diex Recherche Sherbrooke East
Sherbrooke, Quebec, Canada
Status: Open
Clinique des maladies lipidiques de Quebec
Québec, Canada
Status: Open
Cangzhou People's Hospital
Cangzhou, Hebei, China
Status: Open
Huai He Hospital of Henan University
Kaifeng, Henan, China
Status: Open
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
Status: Open
Affiliated Hospital of Jiangsu University
Zhenjiang, Jiangsu, China
Status: Open
Yan'an University Xianyang Hospital
Xianyang, Shaanxi, China
Status: Open
Jinan Central Hospital
Jinan, Shandong, China
Status: Open
The First Affiliated Hospital of Ningbo University
Ningbo, Zhejiang, China
Status: Open
Peking University People's Hospital
Beijing, China
Status: Open
Beijing Pinggu Hospital
Beijing, China
Status: Open
The First Hospital of Jilin University
Changchun, China
Status: Open
The Second People's Hospital of Hefei
Hefei, China
Status: Open
The Fourth Affiliated Hospital of Harbin Medical University
Herbin, China
Status: Open
Huizhou Central People's Hospital
Huizhou, China
Status: Open
Hebei Petro China Central Hospital
Langfang, China
Status: Open
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, China
Status: Open
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, China
Status: Open
Affiliated Drum Tower Hospital of Nanjing University Medical School
Nanjing, China
Status: Open
Pingxiang People's Hospital
Pingxiang, China
Status: Open
Shanghai Pudong New Area People's Hospital
Shanghai, China
Status: Open
Shanghai Fifth People's Hospital Affiliated to Fudan University
Shanghai, China
Status: Open
Siping Central People's Hospital
Siping, China
Status: Open
The First Affiliated Hospital of Soochow University
Suzhou, China
Status: Open
Wuxi People's Hospital
Wuxi, China
Status: Open
The First Affiliated Hospital of Xi'an Medical University
Xi'an, China
Status: Open
Yueyang Central Hospital
Yueyang, China
Status: Open
DIACENTRUM Brandýs nad Labem s.r.o.
Brandýs nad Labem, Czechia
Status: Open
Diavital Jesenice s.r.o.
Jesenice, Czechia
Status: Open
Institut klinické a experimentální medicíny (IKEM);centrum diabetologie
Prague, Czechia
Status: Open
FLEDIP s.r.o.
Prague, Czechia
Status: Open
Úst?ední vojenská nemocnice;Diabetologické centrum
Prague, Czechia
Status: Open
TreDia s.r.o.;Diabetologická ambulance Praha 9
Praha 9 - Klánovice, Czechia
Status: Open
Hopital Saint Joseph Saint Luc
Lyon, France
Status: Open
Hopital de la Conception
Marseille, France
Status: Open
CHU de Nice
Nice, France
Status: Open
European Hospital Georges Pompidou (HEGP)
Paris, France
Status: Open
Chu De Tours
Tours, France
Status: Open
Herz- und Diabeteszentrum NRW Universitätsklinik der Ruhr-Universität Bochum Medizinische Fakultät OWL (Universität Bielefeld);Klinik für Diabetologie und Endokrinologie
Bad Oeynhausen, Germany
Status: Open
Hector-Center für Ernährung, Bewegung und Sport, Universitätsklinikum Erlangen;Medizinische Klinik 1 ? Gastroenterologie, Pneumologie und Endokrinologie
Erlangen, Germany
Status: Open
InnoDiab Forschung GmbH
Essen, Germany
Status: Open
Medizentrum Essen Borbeck
Essen, Germany
Status: Open
Unterfrintroper Hausarztzentrum
Essen, Germany
Status: Open
Universitaets Klinikum Frankfurt - Zentrum der Inneren Medizin
Frankfurt, Germany
Status: Open
MVZ Diabeteszentrum Dr. Tews GmbH;Praxis für Diabetologie
Gelnhausen, Germany
Status: Open
Diabeteszentrum Hamburg West
Hamburg, Germany
Status: Open
Mesut Durmaz - Facharzt für Innere Medizin, Endokrinologie & Diabetologie
Hof, Germany
Status: Open
Zentrum für klinische Forschung Köln - Dünnwald;Dünnwald Praxis
Köln - Dünnwald, Germany
Status: Open
Schwerpunktpraxis für Diabetes und Ernährungsmedizin, Dr. med. Winfried Keuthage
Münster, Germany
Status: Open
Diabetologische Schwerpunktpraxis Pirna Hausärztliche Versorgung
Pirna, Germany
Status: Open
Azienda Ospedaliera Papa Giovanni XXIII
Bergamo, Abruzzo, Italy
Status: Open
Azienda Ospedaliero-Universitaria "Renato Dulbecco" Catanzaro
Catanzaro, Calabria, Italy
Status: Open
A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna
Bologna, Emilia-Romagna, Italy
Status: Open
Umberto I Policlinico di Roma-Università di Roma La Sapienza
Rome, Lazio, Italy
Status: Open
Policlinico Universitario Agostino Gemelli
Rome, Lazio, Italy
Status: Open
Asst Grande Ospedale Metropolitano Niguarda
Milan, Lombardy, Italy
Status: Open
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
Palermo, Sicily, Italy
Status: Open
AO di Perugia - Ospedale S. Maria della Misericordia
Perugia, Umbria, Italy
Status: Open
Kasugai Municipal Hospital
Aichi, Japan
Status: Open
Fukuhama Chuo Clinic
Fukuoka, Japan
Status: Open
NTT Medical Center Sapporo
Hokkaido, Japan
Status: Open
Hasegawa Medicine Clinic
Hokkaido, Japan
Status: Open
The University of Osaka Hospital
Osaka, Japan
Status: Open
The University of Tokyo Hospital
Tokyo, Japan
Status: Open
Higashijujo Sakai Diabetes Internal Medicine Clinic
Tokyo, Japan
Status: Open
Medical Center Metas SC
Col Saucito, Chihuahua, Mexico
Status: Open
Arechavaleta Granell Maria del Rosario
Guadalajara, Jalisco, Mexico
Status: Open
Instituto Jalisciense de investigacion en diabetes y obesidad S.C.
Guadalajara, Jalisco, Mexico
Status: Open
Clinicos Asociados Bocm, S.C.
México, Mexico CITY (federal District), Mexico
Status: Open
Instittuto Nacional de Ciencias Medicas y Nutricion "Salvador Subiran"
México, Mexico CITY (federal District), Mexico
Status: Open
CEMDEC S.A. de C.V.
Delegacion Cuauhtemoc, Mexico, Mexico
Status: Open
Instituto de Diabetes Obesidad y Nutricion, SC
Cuernavaca, Morelos, Mexico
Status: Open
Avant Santé Research Center
San Pedro Garza García, Nuevo León, Mexico
Status: Open
Centro de Estudios de Investigacion Metabolicos y Cardiovasculares SC
Ciudad Madero, Tamaulipas, Mexico
Status: Open
NZOZ Osteo-Medic s.c. A. Racewicz, J.Supronik
Bialystok, Podlaskie Voivodeship, Poland
Status: Open
Centrum Medyczne INTERCOR Sp. z o.o.
Bydgoszcz, Poland
Status: Open
ETG Debica
Dębica, Poland
Status: Open
Ekamed sp. z o.o.
Lublin, Poland
Status: Open
NZOZ Eskulap Pabianice
Pabianice, Poland
Status: Open
Centrum Medyczne OMEDICA
Poznan, Poland
Status: Open
NZOZ Przychodnia Specjalistyczna Andrzej Wittek, Henryk Rudzki s.c.
Ruda Śląska, Poland
Status: Open
ETG Siedlce
Siedlce, Poland
Status: Open
Panstwowy Instytut Medyczny - MSWiA
Warsaw, Poland
Status: Open
NZOZ Regionalna Poradnia Diabetologiczna
Wroclaw, Poland
Status: Open
FDI Clinical Research
San Juan, Puerto Rico
Status: Open
Spitalul Clinic Judetean de Urgenta 'Pius Brinzeu' Timisoara
Timișoara, Romania
Status: Open
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggido, South Korea
Status: Open
Eulji University Hospital
Daejeon, South Korea
Status: Open
Yonsei University Wonju Severance Christian Hospital
Gangwon-do, South Korea
Status: Open
Chosun University Hospital
Gwangju, South Korea
Status: Open
Uijeongbu St. Mary's Hospital
Gyeonggi-do, South Korea
Status: Open
Eulji General Hospital
Seoul, South Korea
Status: Open
Kangbuk Samsung Hospital
Seoul, South Korea
Status: Open
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Status: Open
Gangdong Kyung Hee University Hospital
Seoul, South Korea
Status: Open
Hallym University Kangnam Sacred Heart Hospital
Seoul, South Korea
Status: Open
Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, Spain
Status: Open
Complejo Hospitalario Universitario A Coruña
A Coruña, LA Coruna, Spain
Status: Open
Complejo Hospitalario Universitario de Ferrol
Ferrol, LA Coruna, Spain
Status: Open
Hospital Universitario Quironsalud Madrid
Pozuelo de Alarcón, Madrid, Spain
Status: Open
Centro Medico Teknon
Barcelona, Spain
Status: Open
Hospital Universitari Vall d Hebron
Barcelona, Spain
Status: Open
Hospital Gregorio Marañon
Madrid, Spain
Status: Open
Hospital Universitario Fundacion Jimenez Diaz.
Madrid, Spain
Status: Open
Hospital Universitario Virgen de la Victoria
Málaga, Spain
Status: Open
Nuevas Tecnologias en Diabetes y Endocrinologia
Seville, Spain
Status: Open
Changhua Christian Hospital
Changhua, Taiwan
Status: Open
Chia-Yi Christian Hospital
Chiayi City, Taiwan
Status: Open
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
Status: Open
Chung Shan Medical University Hospital
Taichung, Taiwan
Status: Open
China Medical University Hospital
Taichung, Taiwan
Status: Open
National Cheng Kung University Hospital
Tainan, Taiwan
Status: Open
National Taiwan University Hospital
Taipei, Taiwan
Status: Open
Taipei Veterans General Hospital
Taipei, Taiwan
Status: Open
Rajavithi Hospital
Bangkok, Thailand
Status: Open
Ramathibodi Hospital
Bangkok, Thailand
Status: Open
Siriraj Hospital
Bangkok, Thailand
Status: Open
Division of Endocrinology and Metabolism;Internal Medicine
Chiang Mai, Thailand
Status: Open
Songklanagarind Hospital
Hat Yai, Thailand
Status: Open
Thammasat University Hospital
Khlong Luang, Thailand
Status: Open
Koc University Medical Faculty Hospital
Istanbul, Zeytinburnu, Turkey (Türkiye)
Status: Open
Adana Sehir Egitim ve Arastirma Hastanesi
Adana, Turkey (Türkiye)
Status: Open
Ankara University Medical Faculty
Ankara, Turkey (Türkiye)
Status: Open
Akdeniz University Medical Faculty
Antalya, Turkey (Türkiye)
Status: Open
Kanuni Sultan Suleyman Training and Research Hospital
Istanbul, Turkey (Türkiye)
Status: Open
Medeniyet University Goztepe Training and Research Hospital
Istanbul, Turkey (Türkiye)
Status: Open
Dokuz Eylul University Medicine Faculty
Izmir, Turkey (Türkiye)
Status: Open
Baskent Universitesi - Adana Uygulama Ve Arastirma Merkezi
Sariçam, Turkey (Türkiye)
Status: Open
Fylde Coast Clinical Research at Layton Medical Centre
Blackpool, Lancashire, United Kingdom
Status: Open
Aberdeen Royal Infirmary
Aberdeen, United Kingdom
Status: Open
Antrim Area Hospital
Antrim, United Kingdom
Status: Open
Southmead General Hospital
Bristol, United Kingdom
Status: Open
Ninewells Hospital and Medical School - Tayside Health Board
Dundee, United Kingdom
Status: Open
HMC Health Group
Hounslow, United Kingdom
Status: Open
Hull Royal Infirmary
Hull, United Kingdom
Status: Open
George Eliot Hospital
Nuneaton, United Kingdom
Status: Open
Knowle House Surgery
Plymouth, United Kingdom
Status: Open
Musgrove Park Hospital
Taunton, United Kingdom
Status: Open
Trial Design & Scientific Setup
Allocation
randomized
Intervention Model
parallel
Primary Purpose
treatment
Masking
double (participant, investigator)
Sponsoring Teams & Contacts
Lead Sponsoring Institution
Hoffmann-La Roche
Primary Research Contact
Reference Study ID Number: WC45726 https://forpatients.roche.com/ No attachments to email below.
Tel: 888-662-6728 (U.S. Only)
Clinical Trial Application Copilot
Want to apply or inquire about joining this study? Fill out this simple questionnaire, and our assistant will instantly generate a professional email draft you can copy and send to the central contact coordinator listed above!
Generated Professional Email Draft:
Draft ready to copy & send
Subject: Inquiry about clinical trial enrollment: NCT07351058 - A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Dear Study Coordinator / Research Team,
I hope this message finds you well.
My name is [Your Name], and I am writing to express my strong interest in participating in the clinical trial titled "A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes" (NCT ID: NCT07351058).
I am [Age] years old and have been diagnosed with Obesity or Overweight. I have reviewed the eligibility criteria for this study on Med Code Info and believe I may be a suitable candidate.
Could you please let me know if this study is actively enrolling patients at any site near my location, and what the next steps are to undergo screening?
Thank you for your time and research efforts.
Warm regards,
[Your Name]
View Official Medical/Scientific Title
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight and Type 2 Diabetes